| Course | NURS 6521 Advanced Pharmacology |
|---|---|
| Week | Week 5 |
| Paper type | Antidiabetic class selection brief |
| Length | About 1,080 words, 6 pages |
| Format | APA 7 student paper |
| School | Walden University |
| Program | Master of Science in Nursing (MSN) |
| Updated | October 2026 |
Free sample paper for NURS 6521 Week 5
Selecting a Second Antidiabetic Agent for a 63-Year-Old Man With Type 2 Diabetes and Heart Failure With Reduced Ejection Fraction
Student Name
College of Nursing, Walden University
NURS 6521: Advanced Pharmacology
Instructor Name
Month Day, Year
Selecting a Second Antidiabetic Agent for a 63-Year-Old Man With Type 2 Diabetes and Heart Failure With Reduced Ejection Fraction
Patient
The patient is a composite created for this brief. Mr. G.P. is 63, a retired high school band director, with type 2 diabetes for eight years on metformin, now 1,000 mg with breakfast and again with dinner. Over the past year his hemoglobin A1c has climbed from 7.6 to 8.6 percent. Eighteen months ago a viral illness left him with heart failure and a reduced ejection fraction; his most recent echocardiogram shows an ejection fraction of 30 percent. He is in New York Heart Association class II on sacubitril-valsartan, carvedilol, spironolactone, and furosemide 20 mg daily. His estimated glomerular filtration rate is 66 mL/min/1.73 m2 and stable, and his body mass index is 29. He says clearly that he does not want injections. The decision is which class to add to metformin.
Background: The Type of Diabetes
Type 2 diabetes results from insulin resistance in muscle, liver, and fat combined with a progressive decline in beta cell insulin secretion, so that the pancreas can no longer compensate for resistance. It differs from type 1 diabetes, in which autoimmune destruction of beta cells produces absolute insulin deficiency and insulin is required from diagnosis. The distinction matters for this decision because the agents compared below act on different parts of the type 2 defect, and several of them depend on residual beta cell function that Mr. P. still has (Rosenthal & Burchum, 2021).
Classes Compared
Sodium-glucose cotransporter 2 (SGLT2) inhibitors block the transporter in the proximal tubule that reabsorbs most filtered glucose, so glucose and sodium are lost in the urine independent of insulin. For Mr. P., that mechanism predicts modest glucose lowering, a small natriuretic and diuretic effect, weight loss, and a low risk of hypoglycemia. In heart failure the class does more than lower glucose: in a meta-analysis of five large trials, SGLT2 inhibitors reduced the combined risk of cardiovascular death or hospitalization for heart failure across the range of ejection fractions, in patients with and without diabetes (Vaduganathan et al., 2022).
Glucagon-like peptide 1 (GLP-1) receptor agonists enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite. They lower A1c substantially, promote weight loss, and reduce atherosclerotic cardiovascular events in people with established disease, but they have not shown the same reduction in heart failure hospitalization in reduced ejection fraction. Almost all agents in the class are injected; one oral agent exists. Given his clear preference and the stronger heart failure evidence for SGLT2 inhibitors, this class is deferred rather than excluded, as a later addition if more glucose lowering is needed.
Sulfonylureas close ATP-sensitive potassium channels on beta cells, triggering insulin release regardless of glucose level. That mechanism predicts their two main problems: hypoglycemia, because insulin is released even when glucose is normal, and weight gain from increased insulin. Neither is helpful to a patient with heart failure and a body mass index of 29, and the class has no cardiovascular or renal benefit. It is set aside.
Thiazolidinediones activate the nuclear receptor PPAR-gamma, improving insulin sensitivity in fat and muscle. The same receptor, expressed in the collecting duct, increases sodium and water reabsorption, and fluid retention and edema follow. In a patient with heart failure, that retention can precipitate decompensation; a consensus statement from the American Heart Association and American Diabetes Association advised against their use in patients with advanced heart failure symptoms (Nesto et al., 2003). They are excluded.
Selection
The brief selects an SGLT2 inhibitor, empagliflozin 10 mg daily, added to metformin. The American Diabetes Association Standards of Care recommend an SGLT2 inhibitor with proven benefit for people with type 2 diabetes and heart failure, to reduce heart failure hospitalization, independent of A1c and in addition to metformin where appropriate (American Diabetes Association Professional Practice Committee [ADA], 2024). The choice answers three things documented in Mr. P.: his heart failure with reduced ejection fraction, where the class reduces hospitalization and cardiovascular death; his kidney function, which is adequate for the drug to work and which the class helps protect; and his refusal of injections. The expected A1c reduction on its own is modest, often about 0.5 to 0.7 percentage points, so glucose control is reassessed at three months, when a GLP-1 receptor agonist remains an option if his preferences change.
Two interactions are anticipated. The natriuretic effect adds to furosemide, so volume status is checked early and the loop diuretic dose may be reduced if he becomes lightheaded or his weight falls sharply. Because the combination lowers glucose without raising insulin, hypoglycemia is unlikely with metformin, which is one more reason the sulfonylurea is not needed.
Metformin stays in the regimen. It lowers hepatic glucose production, does not cause hypoglycemia on its own, is weight neutral, and is inexpensive, and with an estimated glomerular filtration rate of 66 it needs no dose change. Older labeling discouraged metformin in heart failure because of concern about lactic acidosis, but that concern applied mainly to unstable or decompensated states with poor tissue perfusion, and metformin is now used routinely in patients with stable heart failure and adequate kidney function (Rosenthal & Burchum, 2021). It is held during acute decompensation, contrast studies, or any illness that threatens kidney perfusion, the same situations in which the SGLT2 inhibitor is paused, so the two drugs share one set of sick-day instructions, which keeps his plan simple.
Patient Education
Mr. P. is told that the new tablet makes his kidneys pass extra sugar and salt in his urine, which lowers his blood sugar and helps his heart. He may urinate more at first. He is told that genital yeast infections are more common with this medicine because of the sugar in the urine, and is taught to keep the area clean and dry and to call if he has itching, discharge, or pain. He is taught sick-day rules: if he cannot eat or drink normally because of vomiting, diarrhea, or illness, or before planned surgery, he stops the tablet and calls, because a rare complication called ketoacidosis can occur even when blood sugar is not very high. He is asked to weigh himself each morning as he already does for his heart failure and to report a drop of more than 3 pounds in two days, dizziness on standing, or very dark urine. His kidney function and potassium are rechecked at the next visit.
References
American Diabetes Association Professional Practice Committee. (2024). 9. Pharmacologic approaches to glycemic treatment: Standards of care in diabetes 2024. Diabetes Care, 47(Suppl. 1), S158-S178. https://doi.org/10.2337/dc24-S009
Nesto, R. W., Bell, D., Bonow, R. O., Fonseca, V., Grundy, S. M., Horton, E. S., Le Winter, M., Porte, D., Semenkovich, C. F., Smith, S., Young, L. H., & Kahn, R. (2003). Thiazolidinedione use, fluid retention, and congestive heart failure: A consensus statement from the American Heart Association and American Diabetes Association. Circulation, 108(23), 2941-2948. https://doi.org/10.1161/01.CIR.0000103683.99399.7E
Rosenthal, L. D., & Burchum, J. R. (2021). Lehne's pharmacotherapeutics for advanced practice nurses and physician assistants (2nd ed.). Elsevier.
Vaduganathan, M., Docherty, K. F., Claggett, B. L., Jhund, P. S., de Boer, R. A., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., Shah, S. J., Desai, A. S., McMurray, J. J. V., & Solomon, S. D. (2022). SGLT-2 inhibitors in patients with heart failure: A comprehensive meta-analysis of five randomised controlled trials. The Lancet, 400(10354), 757-767. https://doi.org/10.1016/S0140-6736(22)01429-5
The Walden NURS 6521 Week 5 instructions
Week 5 of NURS 6521 asks you to select a diabetes medication class for a patient with other conditions. Confirm the diagnosis, compare classes, choose one that fits all the patient's conditions and plan education. Comorbidity integration carries the heaviest weight, so a brief that treats diabetes as the only condition loses it. Cite the ADA Standards and trials in APA 7. Heart failure decides the example because some classes help it and others worsen it. Insulin can be discussed as a later option. The patient is a composite. Explain the mechanism of the chosen class. A comparison table of classes with columns for glucose lowering, heart failure effect, weight, hypoglycemia and cost keeps the reasoning visible.
How the NURS 6521 Week 5 example is put together
Three pages, headed like a consult note but argued like an analysis. A patient paragraph lists the diabetes history, a reduced ejection fraction, stable kidney function and a wish to avoid injections. The comparison section treats four classes in turn: sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 receptor agonists, sulfonylureas and thiazolidinediones, each introduced by its mechanism in one sentence and judged against the heart failure in the next. The thiazolidinedione is excluded for fluid retention, the sulfonylurea set aside for hypoglycemia and weight gain, and the injectable class deferred at his request. The selection paragraph chooses the cotransporter inhibitor, explaining that glucose leaves through the urine and that the class has shown cardiac and renal benefit. Education on genital infection risk and illness-day precautions closes the brief.
NURS 6521 Week 5 rubric: what earns full marks
Comorbidity integration usually carries the heaviest row, and briefs lose it by treating diabetes as the only condition present. Mechanism accuracy is the next concern, especially confusion between classes that raise insulin and classes that act independently of it, which leads to wrong predictions about hypoglycemia. Graders reward exclusions argued from mechanism more than exclusions asserted from a table. The education row expects content tied to the selected agent, and paragraphs covering diet and exercise in general earn partial credit at best. Some prompts include a separate row on types of diabetes, and the example addresses that in a short background paragraph. Citations to current standards matter more here than in most weeks, because recommendations in this area move quickly.
Common NURS 6521 Week 5 mistakes, and how to avoid them
Antidiabetic briefs score poorly when heart failure is mentioned but not used. Let it drive the choice. A second weakness is skipping harmful classes. Explain why thiazolidinediones are avoided. Writers also forget his diuretic. Address volume loss with an SGLT2 inhibitor. Avoid choosing by A1c lowering alone. Weigh outcomes. Include sick day guidance. A sentence noting that his furosemide dose may need review after starting an SGLT2 inhibitor shows integration across his regimen. Close with what you will check at follow-up. Mention genital infection and dehydration risks in the teaching.
Get a NURS 6521 Week 5 example written to your instructions
With the prompt, rubric and patient details your section provides, the brief is argued for that case, comorbidities included. Delivery takes 24 to 48 hours, and the first custom one is free of charge. A different comorbidity, such as chronic kidney disease or obesity, reorders the NURS 6521 Week 5 comparison around whichever one your case names.
More NURS 6521 papers and MSN samples
- NURS 6521 Week 1: Adverse Drug Event Review
- NURS 6521 Week 2: Prescriptive Authority Analysis
- NURS 6521 Week 3: Cardiovascular Drug Therapy Plan
- NURS 6521 Week 4: Stepwise Inhaler Therapy Post
- NURS 6521 Week 6: Gastrointestinal agent choice analysis
- NURS 6521 Week 7: Neurologic prescribing decision tree
- NURS 6521 Week 8: Hormonal agent risk discussion
- NURS 6521 Week 9: Antimicrobial stewardship rationale
- NURS 6521 Week 10: Drug interaction screening report
- NURS 6521 Week 11: Multisystem prescribing synthesis
- NURS 6630 Week 5: Decision tree case
- NURS 6512 Week 5: Skin Lesion Write-Up
- NURS 6710 Week 5: Windshield survey writeup
- NURS 6501 Week 5: Neurologic Deficit Post
NURS 6521 Week 5 questions, answered
Why is heart failure the deciding factor in the example?
Because it separates the classes more sharply than most other comorbidities would. One class worsens fluid retention, another has outcome evidence in heart failure, and two are neutral, so the comparison produces a clear answer that shows the reasoning. If your case centers on kidney disease or weight instead, the same comparison method applies but the ordering changes.
Does the brief include insulin?
It mentions insulin once, as the option held in reserve if non-insulin agents fail to reach the goal agreed with the patient. The prompt behind the example asked for an add-on to metformin in a man reluctant to inject, so insulin initiation falls outside its scope. Where your prompt asks for insulin reasoning, it becomes a full comparison paragraph with its own mechanism and risks.
Was this patient drawn from a real chart?
He is invented, with a history designed to make the comparison instructive rather than taken from any record. The details are plausible, not personal. Your own brief should work from the case your section assigns, and if the prompt invites a patient from clinical practice, strip every identifier before the details appear in a submission.
Where can I find a free NURS 6521 Week 5 sample paper?
The heart failure antidiabetic brief is on this page with the diabetes type, classes compared, the SGLT2 inhibitor selection and education.
Which class is avoided in NURS 6521 Week 5?
Thiazolidinediones such as pioglitazone, because they cause fluid retention and can worsen heart failure.